Burjeel Holdings files for $750M IPO, the largest healthcare listing in UAE history

Burjeel Holdings plans to raise $750 million (AED 2.75 billion) through an IPO on the Abu Dhabi Securities Exchange (ADX), the largest healthcare listing in UAE history, according to filings reviewed by Gulf Business.

The listing would place Burjeel alongside Pure Health and NMC Health's successor entities as publicly traded hospital groups on UAE exchanges. Three healthcare-related IPOs listed on Gulf exchanges in the 18 months before Burjeel's filing, collectively raising more than $2 billion, and institutional appetite for the sector has not slowed.

What Burjeel brings to the public market

Burjeel, founded by Dr. Shamsheer Vayalil, operates more than 40 hospitals, medical centres, and pharmacies across the UAE and Oman. Its flagship is Burjeel Medical City in Abu Dhabi, a 250-bed quaternary care hospital that opened in 2022 with specialties in oncology, organ transplant, and bone marrow transplant. The group reported revenue exceeding AED 4 billion in the 12 months before the filing, driven by Abu Dhabi's mandatory insurance volumes and its medical tourism corridor.

The company operates across the full acuity spectrum through four distinct brand tiers:

• Burjeel — premium tertiary and quaternary hospitals
• Medeor and LLH — mid-tier secondary care facilities
• Tajmeel — primary care and cosmetic clinics

This multi-tier structure mirrors the strategy that made NMC Health attractive to investors before its 2020 collapse, though Burjeel has worked to distance itself from that comparison.

Regulatory tailwinds across both emirates

The IPO arrives during a period of heavy government investment in healthcare infrastructure. The Department of Health Abu Dhabi (DOH) expanded mandatory health insurance to cover all residents, which created a guaranteed revenue floor for licensed providers. Abu Dhabi's population grew by an estimated 4.2% in 2021, and DOH approved new hospital licences at twice the rate of the previous five-year period.

Dubai's Dubai Health Authority (DHA) and the federal Ministry of Health and Prevention (MOHAP) have similarly expanded coverage mandates and licensed new facilities across the Northern Emirates. For Burjeel, which operates in both Abu Dhabi and Dubai, the cross-emirate regulatory environment creates a large addressable market without the fragmented licensing barriers that constrain smaller operators.

What operators and CFOs should watch

For competing hospital groups, Burjeel's IPO creates two immediate pressures. A publicly listed Burjeel with $750 million in fresh capital will have significant firepower for acquisitions, particularly in Oman and the wider GCC where consolidation is accelerating. The IPO prospectus will also disclose detailed financials, including per-bed revenue, occupancy rates, and payer mix, that become the benchmark against which private operators are measured by insurers, regulators, and lenders.

CFOs at mid-size hospital groups should expect board-level questions about whether their margins and growth rates compare favourably to Burjeel's disclosed figures. CIOs should note that Burjeel invested heavily in electronic health record (EHR) integration and clinical AI as part of its pre-IPO positioning. DOH may tie future facility accreditation to digital maturity standards, and Burjeel's disclosures will set the bar.

The listing timeline points to Q4 2022, subject to Securities and Commodities Authority (SCA) approval and market conditions.